Nomura has issued a research report expecting JD HEALTH (06618.HK) +1.750 (+3.834%) Short selling $42.09M; Ratio 20.827% 's 1H25 revenue and earnings to be better than expected.In Nomura's estimate, JD HEALTH's total revenue for 2Q25 will grow by 16% YoY, with sales of pharmaceuticals/ nutritional products/ medical equipment increasing by over 20%/ around 15%/ around 11%.Related NewsPing An Securities Outlines Key Differences Between Stablecoins/ Virtual Currencies/ Central Bank Digital Currencies (Table)In addition, JD-SW (09618.HK) -0.400 (-0.321%) Short selling $69.18M; Ratio 16.618% (JD.US) , JD HEALTH's parent company, actively invested in its food delivery and rapid delivery operations in 2Q, which may bring unexpected benefits to JD HEALTH's business. Its core B2C business may benefit from users utilizing the JD app, while its thriving on-demand sales business could benefit from JD.com's continuously growing delivery network.Nomura raised its target price for JD HEALTH from HKD49 to HKD52 and kept the Buy rating unchanged.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-17 12:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)